BRPI1011710A8 - lágrimas artificiais e usos trapêuticos - Google Patents

lágrimas artificiais e usos trapêuticos Download PDF

Info

Publication number
BRPI1011710A8
BRPI1011710A8 BRPI1011710A BRPI1011710A BRPI1011710A8 BR PI1011710 A8 BRPI1011710 A8 BR PI1011710A8 BR PI1011710 A BRPI1011710 A BR PI1011710A BR PI1011710 A BRPI1011710 A BR PI1011710A BR PI1011710 A8 BRPI1011710 A8 BR PI1011710A8
Authority
BR
Brazil
Prior art keywords
oil
artificial tears
traumatic
syndrome
dog
Prior art date
Application number
BRPI1011710A
Other languages
English (en)
Inventor
V Gore Anuradha
Pujara Chetan
Krock Kevin
S Jordan Robert
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42312750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011710(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI1011710A2 publication Critical patent/BRPI1011710A2/pt
Publication of BRPI1011710A8 publication Critical patent/BRPI1011710A8/pt
Publication of BRPI1011710B1 publication Critical patent/BRPI1011710B1/pt
Publication of BRPI1011710B8 publication Critical patent/BRPI1011710B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"lágrimas artificiais e usos trapêuticos". a presente invenção refere-se a composições oftálmicas, por exemplo lágrimas artificiais, apropriadas para o tratamento da síndrome do olho seco em um ser humano ou outro mamífero sofrendo de tal síndrome, por exemplo, um cachorro ou gato, que compreende uma mistura de óleo de mamona com outro óleo, por exemplo, um óleo alimentício, por exemplo azeite de oliva, óleo de gergelim, óleo de milho e etc.
BRPI1011710A 2009-06-05 2010-06-03 composição para ser usada como uma lágrima artificial BRPI1011710B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18433909P 2009-06-05 2009-06-05
US61/184,339 2009-06-05
PCT/US2010/037153 WO2010141648A2 (en) 2009-06-05 2010-06-03 Artificial tears and therapeutic uses

Publications (4)

Publication Number Publication Date
BRPI1011710A2 BRPI1011710A2 (pt) 2016-03-22
BRPI1011710A8 true BRPI1011710A8 (pt) 2019-11-05
BRPI1011710B1 BRPI1011710B1 (pt) 2021-01-26
BRPI1011710B8 BRPI1011710B8 (pt) 2021-05-25

Family

ID=42312750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011710A BRPI1011710B8 (pt) 2009-06-05 2010-06-03 composição para ser usada como uma lágrima artificial

Country Status (24)

Country Link
US (6) US8496976B2 (pt)
EP (1) EP2437762B1 (pt)
KR (1) KR101778316B1 (pt)
CN (2) CN102458430A (pt)
AU (1) AU2010256652B2 (pt)
BR (1) BRPI1011710B8 (pt)
CA (1) CA2764802A1 (pt)
DK (1) DK2437762T3 (pt)
ES (1) ES2646338T3 (pt)
HK (1) HK1214943A1 (pt)
HR (1) HRP20171691T1 (pt)
HU (1) HUE034213T2 (pt)
IL (1) IL216800A (pt)
LT (1) LT2437762T (pt)
MX (2) MX2011013007A (pt)
MY (1) MY172185A (pt)
NO (1) NO2437762T3 (pt)
NZ (1) NZ596932A (pt)
PL (1) PL2437762T3 (pt)
PT (1) PT2437762T (pt)
RU (1) RU2589837C2 (pt)
SI (1) SI2437762T1 (pt)
WO (1) WO2010141648A2 (pt)
ZA (1) ZA201108979B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
NZ596932A (en) 2009-06-05 2014-04-30 Allergan Inc Artificial tears and therapeutic uses
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9314528B2 (en) * 2011-12-07 2016-04-19 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
WO2013142912A1 (en) 2012-03-30 2013-10-03 Brien Holden Vision Institute Methods and compositions for reducing ocular discomfort
US9289494B2 (en) * 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
ES2781114T3 (es) 2014-08-20 2020-08-28 Silk Tech Ltd Composición proteica derivada de fibroína
MX2017006474A (es) * 2014-11-25 2017-09-12 Allergan Inc Composiciones oftalmicas estabilizadas de omega 3.
US10286035B2 (en) 2015-10-14 2019-05-14 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
CA3020342A1 (en) 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein
RS58292B1 (sr) * 2016-07-07 2019-03-29 Salvat Lab Sa Oftalmološka kompozicija sa ricinusovim uljem i srednjim lancem triglicerida
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
JP2020532490A (ja) * 2017-06-30 2020-11-12 ジェニヴィジョン インク． 発毛のための製剤
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
US11197841B2 (en) 2019-07-23 2021-12-14 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
KR20210038635A (ko) 2018-07-27 2021-04-07 존슨 앤드 존슨 서지컬 비전, 인코포레이티드 눈 치료용 조성물 및 방법
WO2020021481A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating the eye
US11166997B2 (en) 2018-07-27 2021-11-09 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
KR20210038636A (ko) 2018-07-27 2021-04-07 존슨 앤드 존슨 서지컬 비전, 인코포레이티드 눈 치료용 조성물 및 방법
AU2019311849B2 (en) 2018-07-27 2023-06-08 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11110051B2 (en) 2018-08-30 2021-09-07 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and n-acetyl glucosamine
US11045416B2 (en) 2018-08-30 2021-06-29 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and retinol
KR20210009947A (ko) 2019-07-18 2021-01-27 윤영선 산소가 도입된 점안제, 및 그 제조방법
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
EP3824895A1 (en) 2019-11-19 2021-05-26 Johnson & Johnson Consumer Inc. Compositions and methods for treating the eye
EP3824877A1 (en) 2019-11-19 2021-05-26 Johnson & Johnson Consumer Inc. Compositions and methods for treating the eye
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
EP4059508A1 (en) 2021-03-19 2022-09-21 Johnson & Johnson Consumer Inc. Methods of using compositions comprising an iceland moss extract

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104814A (en) * 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
BE1003578A4 (fr) * 1988-10-26 1992-04-28 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine.
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
GB0012597D0 (en) 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
US7027446B2 (en) 2001-07-18 2006-04-11 P-Cube Ltd. Method and apparatus for set intersection rule matching
JP4284491B2 (ja) 2002-07-16 2009-06-24 豊和工業株式会社 ピストン外形の加工データ生成装置
UY28126A1 (es) * 2002-12-24 2004-06-30 Alcon Inc Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
JP5475215B2 (ja) * 2003-02-24 2014-04-16 ファーマシューティカル プロダクションズ， インコーポレイテッド 経粘膜薬物送達システム
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
MX2007000208A (es) 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
MX2007002400A (es) * 2004-08-27 2007-05-04 Senju Pharma Co Liquido para lavado de ojos para terapia de ojos secos.
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CN100562340C (zh) * 2005-06-17 2009-11-25 中国科学院上海药物研究所 一种微乳型人工泪液
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CA2679448A1 (en) * 2007-02-28 2008-09-04 Aciex, Inc. Methods and compositions for normalizing meibomian gland secretions
CN101554369B (zh) * 2008-05-12 2012-07-25 陈亚玲 一种外用复合油纳米乳喷雾剂和滴眼剂及其制备方法
UA36915U (uk) * 2008-05-28 2008-11-10 Львівський Національний Медичний Університет Ім. Данила Галицького Очні краплі для лікування запальних захворювань судинної оболонки та сухого кератокон'юнктивіту, які викликані аутоімунними процесами
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
NZ596932A (en) 2009-06-05 2014-04-30 Allergan Inc Artificial tears and therapeutic uses

Also Published As

Publication number Publication date
CA2764802A1 (en) 2010-12-09
BRPI1011710B8 (pt) 2021-05-25
RU2011151468A (ru) 2013-07-20
BRPI1011710B1 (pt) 2021-01-26
SI2437762T1 (en) 2018-02-28
EP2437762A2 (en) 2012-04-11
RU2589837C2 (ru) 2016-07-10
US8679554B2 (en) 2014-03-25
HK1214943A1 (zh) 2016-08-12
ES2646338T3 (es) 2017-12-13
US11045515B2 (en) 2021-06-29
US8496976B2 (en) 2013-07-30
US20180264063A1 (en) 2018-09-20
DK2437762T3 (da) 2017-11-20
IL216800A (en) 2017-03-30
CN104906170A (zh) 2015-09-16
MX2011013007A (es) 2012-02-28
US20130295206A1 (en) 2013-11-07
US20120201910A1 (en) 2012-08-09
WO2010141648A3 (en) 2011-03-10
NO2437762T3 (pt) 2018-01-06
US20240108677A1 (en) 2024-04-04
BRPI1011710A2 (pt) 2016-03-22
HUE034213T2 (en) 2018-01-29
MY172185A (en) 2019-11-15
US9821020B2 (en) 2017-11-21
PL2437762T3 (pl) 2018-01-31
WO2010141648A2 (en) 2010-12-09
MX358504B (es) 2018-08-21
CN102458430A (zh) 2012-05-16
AU2010256652B2 (en) 2015-11-26
IL216800A0 (en) 2012-02-29
HRP20171691T1 (hr) 2017-12-15
US20220008496A1 (en) 2022-01-13
PT2437762T (pt) 2017-11-14
EP2437762B1 (en) 2017-08-09
KR101778316B1 (ko) 2017-09-13
US20140141106A1 (en) 2014-05-22
LT2437762T (lt) 2017-11-27
ZA201108979B (en) 2012-08-29
KR20120046151A (ko) 2012-05-09
AU2010256652A1 (en) 2012-01-12
NZ596932A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
BRPI1011710A8 (pt) lágrimas artificiais e usos trapêuticos
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
EA202091999A3 (ru) Применение ингибиторов dpp iv
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BR112012005835A2 (pt) alteração da temperatura em um corpo de mamífero
IL186741A0 (en) Optical probe for delivery of light
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
GT200900146A (es) Inhibidores de la actividad de la akt
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
IN2012DN03178A (pt)
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF